-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Luye Pharmaceutical Group announced that the clinical trial application for nivolumab injection (LY01015) developed by its subsidiary Boan Biotechnology has been accepted by the Drug Evaluation Center of the National Medical Products Administration.
LY01015 is the first biosimilar of Opdivo® (Odivo®) declared in accordance with the 3.
Tumor immunotherapy represented by PD-1 inhibitors has become one of the main methods of cancer treatment in China and even globally.
As the world's first PD-1 immune checkpoint inhibitor approved by regulatory agencies, nivolumab injection has become an important choice for the treatment of a variety of tumors, and has been approved for more than a dozen indications worldwide.
Note: The original text has been deleted